TerminatedNCT00483535
Oral Contraceptive Interaction Study for GW273225
Medication studyAges 18–45United KingdomBipolarity
Understand this study
Who could participate?
Listed age limits: 18 years to 45 years.
- Listed locations
- CambridgeSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 7, 2007
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 12
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT00483535
- Official title
Show the full official title
An Open, Repeat Dose Study to Investigate the Effect of Co-administration of the Combined Oral Contraceptive Pill (COC) and GW273225 on the Pharmacokinetics of the COC and to Investigate the Effects of the COC on the Pharmacokinetics of GW273225 in Healthy Female Subjects
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Does this study involve medication?
Yes. The study involves medication, including GW273225 and COC.
Who can participate?
Listed age limits: 18 years to 45 years.
Is this study still recruiting?
The registry lists this study as terminated.
